To include your compound in the COVID-19 Resource Center, submit it here.

Vyvanse lisdexamfetamine: Phase II data

Data from the open-label portion of the U.S. Phase II Study 204 trial in 92 patients showed that Vyvanse as adjunctive treatment to atypical antipsychotics met the primary endpoint of significantly improving modified SANS-18 total

Read the full 353 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE